Social Cognition, Memory, and Executive Functions in Bipolar Disorder and Major Depressive Disorder
NCT ID: NCT06740331
Last Updated: 2025-01-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
180 participants
INTERVENTIONAL
2025-01-07
2028-02-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aims to explore social cognition deficits (e.g., emotional processing, theory of mind, attribution bias) and their relationship with executive functions (e.g., flexibility, inhibition, working memory) and memory in bipolar disorder and major depressive disorder, ultimately seeking to improve understanding of their functional outcomes.
Social cognition and executive functions in BD are both state- and trait-related. One recent meta-analysis demonstrated impairment in social cognitive domains for manic, depressive, and euthymic bipolar disorders' patients but it remains unclear whether these social cognitive deficits in BD are due to executive functions and/or other confounding effects.
Few studies have investigated the interdependency between these cognitive impairments in these two affective disorders while a better understanding of the link between executive functions and social cognition seems crucial in order to better characterize the nature of patients' deficits and thus their caring.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial of Functional Remediation in Patients With Bipolar Disorder
NCT04577508
Study Efficacy of Enhancing Cognitive Reserve in Patients With a First Bipolar Episode
NCT06081634
Antidepressant Treatments and Cognitive Function of Bipolar Patients
NCT04564573
Facial Emotion Recognition in Patients With Euthymic Bipolar Disorder I and II
NCT05922956
Mental Time Travel and Identity in Bipolar Disorder Patients
NCT02793518
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In addition to delayed diagnoses, the periods between symptomatic episodes, which are considered "stable," are not without challenges. Even during these euthymic periods, individuals often experience residual difficulties that impact their daily functioning. While these periods are viewed as symptom-free, it's clear that individuals still do not experience a significantly improved quality of life. Functional outcomes (e.g., occupational and social functioning) are often impaired and distinguishing between BD and MDD more clearly could improve care and enhance their quality of life. Identifying distinctive markers is essential for improving treatment strategies.
Cognitive functions might serve as trait markers of the disorders because they are impaired both during acute episodes and euthymic phases. These cognitive impairments could also predict functional outcomes in BD. Cognitive profiles may also help distinguish between BD and MDD. While impairments in executive functions, such as the ability to adapt to new situations (e.g., task-switching) and episodic memory (i.e., memory of specific personal events), are present even during euthymic phases of BD, this is not always the case for social cognition (e.g., facial emotion recognition). These cognitive alterations are highly heterogeneous across patients, and identifying their cognitive profiles could provide valuable insights.
Studying the links between cognitive components in BD and MDD may lead to a better understanding how cognitive functions are impacted in these mood disorders, and especially to understand the interactions between these different functions. Additionally, considering clinical symptomatology (e.g., the number of episodes) and other factors (e.g., anxiety, childhood trauma, social support) could offer a more comprehensive understanding of these disorders.
In addition to focusing on these two clinical populations, we will also include first-degree relatives of individuals with bipolar disorder. Indeed, it seems that these relatives may also experience mild cognitive impairments, and we aim to further investigate these hypotheses.
This project aims to better understand social cognition impairments (e.g., emotion processing, theory of mind, attribution bias) and their relationship with verbal episodic memory and executive functions (e.g., working memory, cognitive flexibility) in BD and MDD. It will also explore how these cognitive processes affect functional outcomes in these groups.
A first visit will be dedicated to the collection of clinical data. During the second visit, the investigators will conduct a comprehensive neuropsychological assessment to evaluate executive functions, episodic memory, and all components of social cognition. This protocol will allow the investigators to study all these variables together and to clarify and better understand the connections between them.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bipolar patients
Patients with a diagnosis of bipolar disorder
Analysis of social cognition, memory functioning, and executive functioning processes
Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment
Major depressive patients
Patients with a diagnosis of major depressive disorder
Analysis of social cognition, memory functioning, and executive functioning processes
Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment
First-degree relatives of bipolar patients
First-degree relatives of bipolar patients
Analysis of social cognition, memory functioning, and executive functioning processes
Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment
Bipolar controls
Healthy control participants matched to group 1
Analysis of social cognition, memory functioning, and executive functioning processes
Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment
Depressive controls
Healthy control participants matched to group 2
Analysis of social cognition, memory functioning, and executive functioning processes
Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment
First-degree controls
Healthy control participants matched to group 3
Analysis of social cognition, memory functioning, and executive functioning processes
Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Analysis of social cognition, memory functioning, and executive functioning processes
Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having a diagnosis of bipolar disorder or depressive disorder
* No substantial change in treatment for 2 weeks preceding study enrollment
* Being a native French speaker
* Patients enrolled in the national healthcare insurance program
* Consenting to participate to the study
* Participants between 18 and 65 years old, men or women
* Participants having at least one first-degree relative presenting an bipolar disorder (parents, children, siblings)
* Being a native French speaker
* Patients enrolled in the national healthcare insurance program
* Consenting to participate to the study
* Participants between 18 and 65 years old, men or women
* Being a native French speaker
* Patients enrolled in the national healthcare insurance program
* Consenting to participate to the study
Exclusion Criteria
* A significant general medical illness, including neurological disorders or head trauma
* A sensorial impairment uncorrected (visual and/or hearing)
Group 3: First-degree relatives of bipolar patients
* A diagnosis of schizophrenia or of bipolar disorder or of depressive disorder according to DSM-5 criteria
* The presence of any alcohol use disorder or any other substance use disorder in the last six months, except for tobacco dependence
* A significant general medical illness, including neurological disorders or head trauma
* A sensorial impairment uncorrected (visual and/or hearing)
Group 4, 5, 6: Healthy control participants
* A diagnosis of schizophrenia or of bipolar disorder or of major depressive disorder according to DSM-5 criteria
* The presence of any alcohol use disorder or any other substance use disorder in the last six months, except for tobacco dependence
* Participants having one first-degree relative presenting an bipolar disorder or depressive disorder or schizophrenia according to DSM-5 criteria
* A significant general medical illness, including neurological disorders or head trauma
* A sensorial impairment uncorrected (visual and/or hearing)
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CHU de Reims
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Reims
Reims, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PO24114*
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.